Kala Bio Inc (NAS:KALA)
$ 6 -0.15 (-2.44%) Market Cap: 16.90 Mil Enterprise Value: 5.41 Mil PE Ratio: 0 PB Ratio: 2.53 GF Score: 46/100

Q1 2019 Kala Pharmaceuticals Inc Earnings Call Transcript

May 09, 2019 / 12:00PM GMT
Release Date Price: $347 (-2.25%)
Operator

Good morning, and welcome to Kala Pharmaceuticals First Quarter 2019 Earnings Conference Call. (Operator Instructions) As a reminder, this call is being recorded.

I would now like to turn the call over to Mary Reumuth, Chief Financial Officer for Kala Pharmaceuticals. Please proceed, ma'am.

Mary Reumuth
Kala Pharmaceuticals, Inc. - CFO & Treasurer

Thank you, operator. And thank you all for participating in today's call. Joining me from the company are Mark Iwicki, Chairman, President and Chief Executive Officer; Kim Brazzell, Chief Medical Officer; Todd Bazemore, Chief Operating Officer; and Hongming Chen, Chief Scientific Officer.

Today's call is being webcast live, and the webcast link can be found in the Investors & Media section on the Kala corporate website, kalarx.com.

During this call, we will be referring to non-GAAP financial measures, which are not prepared in accordance with generally accepted accounting principles. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot